A Chinese research team has developed a malignant cancer inhibitor.

Medical Network September 27th reporter 25 from the Chinese Academy of Sciences Hefei Research Institute was informed that the institute's researchers have developed a malignant cancer inhibitor.
evaluation of drug effectiveness in animals showed that the tumor suppression rate (TGI) reached 96%.
the results are now published online in the international journal Signal Transduction and Targeted Therapy.
recently, Liu Qingsong, a researcher at the Institute of Health and Medical Technology of the Hefei Research Institute of the Chinese Academy of Sciences, and Liu Jing, a researcher in pharmacy, developed a new generation of highly selective, highly active BTK kinase inhibitor CHMFL-BTK-85 for B-cell non-Hodgkin's lymphoma.
B-cell non-Hodgkin's lymphoma is a common malignant cancer with a incidence rate of 10-15 per 100,000, which increases with age and has a low survival rate.
Bruton Tyrosine Kinase (BTK) is a non-subject tyrosine kinase, and numerous studies have shown that overexposed and active BTK kinase is one of the leading causes of this type of cancer.
previous studies, the team has developed a range of BTK kinase inhibitors with independent intellectual property rights through drug design and high-volume screening.
in order to further improve its activity, selectivity and pharmacy, the research team continued to develop CHMFL-BTK-85, a small molecule inhibitor with good medicinal ability, through structurally based drug design methods.
at the protein and cellular levels showed that the inhibitor significantly reduced the inhibition of Immune cell-mediated ADCC compared to the listed BTK inhibitor Erudini.
In the evaluation of drug effectiveness in animals, the inhibitor was able to significantly inhibit the growth of subsoculation transplant tumors in mice constructed by TMD8 cells at a dose of 100 mg/kg/day, and the tumor suppression rate (TGI) reached 96%, which significantly extended the survival time of animals in mouse intation tumor models constructed by REC-1 cells.
current research team is conducting further preclinical drug evaluation of CHMFL-BTK-85 with a view to rapidly promoting the drug into industrial development.
.